LAG3 and neoplasm: By contrast, among patients in the advanced disease setting, there were higher levels of LAG-3-expressing T cells in the blood at baseline (Fig. 4b) and a greater magnitude of increase in LAG-3+ T cells upon treatment with nivolumab plus relatlimab than in patients treated in the adjuvant disease setting after tumor resection (Fig. 4c).